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Flow cytometric S-phase fraction (SPF) has been shown to have
independent prognostic value in soft tissue sarcoma (STS)
(Huuhtanen et al, 1996; Collin et al, 1997; Gustafson et al, 1997).
However, in these series, SPFs have been calculated in different
ways, using different corrections for background in the DNA
histograms. The traditional way is the planimetric method of
Baisch et al (1975), where the S-phase compartment is assumed to
constitute a rectangular distribution between the modal values of
the G0/G1 and G2 peaks. This method is hampered by the fact that
SPF can only be calculated in six out of ten STS (Collin et al,
1997; Gustafson et al, 1997), the failures primarily due to (1) a
high background noise distribution; (2) a small non-diploid peak;
and (3) a high coefficient of variation. If one of these criteria is
fulfilled, SPF should, according to international consensus guide-
lines, not be calculated (Shankey et al, 1993). Recently, several
computerized programs have been introduced, where the SPF
value is calculated using mathematical descriptions of the
histogram and the least square curvefitting technique. These
models have a theoretical advantage in promising a higher rate in
calculation of SPF in histograms with high background and/or
small G0/G1 peaks. There is no consensus on which technique for
S-phase fraction gives the most accurate and clinically useful SPF
value. We therefore examined 259 STS, using the Baisch method
and the MultiCycle method, and compared the various models
using metastasis-free survival as end point.
MATERIAL AND METHODS
Patients
The population-based database at the Musculoskeletal Tumor
Center in Lund, Sweden holds 508 patients with STS of extremity
and trunk wall diagnosed between 1964 and 1989. Patients have
been identified via the Regional Tumor Registry. The database
therefore comprises all patients in the Southern Swedish Health
Care Region (1.5 million inhabitants), irrespective of whether the
patients have been treated at our institution or at local hospitals in
the region. Criteria for inclusion as well as classification of treat-
ment, histopathology, including microscopic tumour necrosis,
vascular invasion and malignancy grading, have been described
elsewhere (Gustafson, 1994). In 260 of these 508 patients,
paraffin-embedded material could be retrieved for flow cytometric
DNA analysis. After the DNA analysis was done, one tumour was
reclassified from low-grade STS to benign, and thus 259 patients
remained for analysis.
The 259 patients had a median age of 64 (range 18—90) years,
and a median tumour size of 7 (range 1—40) cm. Two patients
had metastasis at diagnosis (one pulmonary, one lymph nodes).
Malignant fibrous histiocytoma (MFH) was the commonest histo-
type, and grade IV (four-grade scale) the commonest malignancy
grade (Table 1). All but one patient were operated on; 75 patients
had inadequate local treatment (surgery with an intralesional
margin with or without radiotherapy or surgery with a marginal
margin without radiotherapy: 26 at the Musculoskeletal Tumor
Center and 49 at non-Center hospitals), and 183 patients had
adequate local treatment (surgery with a marginal margin with
radiotherapy or surgery with a wide or radical margin with or
without radiotherapy: 158 at the Center and 25 at non-Center
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Correspondence to: P Gustafsonhospitals). Twenty-nine patients received chemotherapy, three of
whom received it preoperatively. These patients were not sepa-
rately analysed, since they did not differ from those who did not
receive chemotherapy as regards clinico-pathologic factors or
outcome.
The median follow-up time for the 89 patients alive at last
follow-up was 16 (range 7—32) years. Eighty-three patients devel-
oped local recurrence, 42 of the 74 treated outside the Center and
41 of the 184 treated at the Center. At latest follow-up 100 patients
had developed distant metastasis, giving a 5-year metastasis-free
survival rate (MFSR) of 0.63.
Compared to the population-based database, the 259 patients
were a representative subset as regards age, sex, tumour localiza-
tion, tumour depth, tumour size, malignancy grade, microscopic
tumour necrosis, vascular invasion, local treatment, metastasis rate
and length of follow-up. In the present series liposarcoma was
more common (15% vs 10%) than in the database, and
leiomyosarcoma was less common (18% vs 25%).
Flow cytometric DNA analysis
One representative paraffin-embedded block was chosen for dis-
integration and analysis. A 4-mm section adjacent to the 100-mm
section for disintegration was stained with haematoxylin and eosin
and served as control to ensure that preserved and non-necrotic
sarcoma tissue was analysed. The DNA analysis was performed
principally according to Schutte et al (1985), including treatment
with trypsin and staining with propidium iodide. The DNA content
in individual nuclei was analysed in an Ortho 50 H cytofluoro-
graph (Baldetorp et al, 1989).
S-phase fraction
Baisch SPF was calculated with a planimetric method (Baisch
et al, 1975) assuming the S-phase compartment to constitute a
rectangular distribution between the modal values of the G0/G1
and G2 peaks, and was expressed as the percentage of nuclei in the
S-phase of the total number of nuclei. In case of bimodality in the
2C region, i.e. neardiploidy with a DNA index (DI) for the non-
diploid stemline below approximately 1.3, a mean SPF value for
the diploid and non-diploid stemline was calculated. When the DI
exceeded 1.3, and if the corresponding G2 peaks were distinctly
separated, the SPF was calculated exclusively for the non-diploid
stemline. In case of two or more non-diploid peaks, the SPF was
calculated in the most prominent non-diploid stemline. SPF was
not calculated if the corresponding G2 peak in the histogram
could not be identified, or if the non-diploid stemline was small
(G0/G1 < 15% of the total number of observations), or if the
coefficient of variation (CV) of the G0/G1 peak exceeded 8%, or if
the contribution of debris in the SPF compartment of the
histogram was too extensive (Shankey et al, 1993). Nuclear
aggregates were gated out using thresholding capabilities of the
DNA analysis software in the Ortho 2140 data handling system.
MultiCycle  The SPF was calculated using the commercial
MultiCycle software (version 3.1.1, Phoenix Flow System, San
Diego, CA, USA). This software is based on the non-linear least
square curve-fitting method described by Marquardt (1963). All
G0/G1 peaks and G2 peaks in the DNA histogram were fitted
by Gaussians and without restrictions on the CV values of the
G2 peak (free from the CV of the G0/G1 peak). Furthermore,
the S-phase compartment was always fitted by a zero order
polynomial (y = constant). The SPF was calculated in five
different ways:
1. Without any background correction (= subtraction) (in Tables
2 and 3 denoted ￿no corr￿).
2. With a cell-related exponential background correction (in
Tables 2 and 3 denoted ￿exp￿).
3. With a cell-related exponential background correction
including nuclear aggregate compensation based on the
random probabilistic nuclear aggregation theory, as described
in the MultiCycle operators manual (in Tables 2 and 3 denoted
￿exp-clust￿).
4. With a sliced nuclei background fit including an exponential
function for the left-most events in the DNA histogram (in
Tables 2 and 3 denoted ￿slice￿).
5. With a sliced nuclei background fit including an exponential
function for the left-most events in the DNA histogram
including nuclear aggregate compensation based on the
random probabilistic nuclear aggregation theory, as described
in the MultiCycle operators manual (in Tables 2 and 3 denoted
￿slice-clust￿).
Criteria for S-phase calculation were used according to the
guidelines in Baldetorp et al (1995) and the recommendations
described in the MultiCycle operators manual.
Statistics
The data were analysed using the c2 test with the Yates continuity
correction when indicated. Analyses of MFSR were univariately
performed with Kaplan—Meier methods and the generalized
Wilcoxon test.
RESULTS
Successful calculations
SPF could be calculated in 159 of the 259 patients using the Baisch
method; the reasons for failure were high background distribution
and/or a small non-diploid peak and/or a high CV. SPF could be
calculated in 253 patients using the MultiCycle program, the
reasons were a high CV and/or no G2 peak. The mean SPF values
varied between 6.0% and 13.6% and the median values varied
between 4.0% and 11.5% depending on which method was used.
Regardless of method used, the median SPF values were at least
three times as high for aneuploid tumours as for euploid tumours
(Table 2).
Prognostic separation
For each method the prognostic strength was analysed using the
cut-off at (1) the median SPF value, (2) at 3.0%, and (3) at the
optimum for each method. The cut-off value chosen was the one
which gave the largest separation in MFSR at 5 years between the
group with good prognosis and the one with poor prognosis. This
cut-off value varied between 3.0% and 9.0%; lowest for Baisch
and for MultiCycle with exponential background correction, and
highest for MultiCycle without background correction and for
MultiCycle with background correction for sliced nuclei.
The best separation in 5-year MFSR between the good prog-
nosis group and the poor prognosis group was seen using the
Baisch method with cut-off value at 3.0%; 0.94 vs 0.53 (Table 2).
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The Baisch method was better than the others in identifying
patients with late first metastasis; four out of seven patients with
SPF 0—3.0% according to Baisch had their first metastases diag-
nosed after 5 years. No other method could demonstrate this
phenomenon (Table 2).
Subgroup analysis
In the 159 patients in whom SPF calculation according to Baisch
was successful, the best prognostic separation in metastasis-free
survival at 5 years was found using MultiCycle with cell-related
exponential background correction and with nuclear aggregate
compensation based on the random probabilistic nuclear aggrega-
tion theory (￿exp-clust￿). The Baisch method again was the best for
identification of patients with late first metastasis (Table 3).
DISCUSSION
SPF has been identified as a prognostic factor in several malignan-
cies: breast cancer, non-small cell lung cancer, colorectal cancer,
carcinoma of the ovary, endometrial cancer, prostate cancer
(Merkel and McGuire, 1990; Sigurdsson et al, 1990;
Gudmundsson et al, 1995; Bratt et al, 1996) and recently in STS
(Huuhtanen et al, 1996; Collin et al, 1997; Gustafson et al, 1997).
The quality of the DNA histogram may depend on several
factors:
1. The contribution from cellular debris may cause different
background patterns in the histogram depending on tumour
type
2. The background may vary depending on whether the specimen
is derived from a fresh—frozen or paraffin-embedded material.
For S-phase calculation specifically, the question arises how to
handle the background contribution from cellular debris and/or
nuclear aggregates. The traditional non-parametric model described
by Baisch et al (1975) is based on finding a region of the S-phase
compartment minimally influenced by debris and aggregates
(Baldetorp et al, 1995). Thus, a visual correction for obvious
Mathematical models for S-phase fraction 1207
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Table 1 Clinico-pathologic data, metastasis-free survival, and crude
metastasis rates in 259 surgically treated patients with soft tissue sarcoma of
extremity and trunk wall
5-year Crude metastasis
Factor/Criteria n MFSR n
Age
≤ 64 years 133 0.64 53
> 64 years 126 0.60 47
Sex
Male 145 0.60 58
Female 114 0.66 42
Localization
Upper extremity proximal 36 0.66 15
Upper extremity distal 17 0.73 4
Trunk wall 34 0.49 16
Lower extremity proximal 125 0.60 51
Lower extremity distal 47 0.74 14
Depth
Subcutaneous 78 0.76 19
Deep-seated 181 0.57 81
Tumour size (cm)
1–5 88 0.77 21
6–10 110 0.61 44
11–15 38 0.49 21
16 and larger 23 0.35 14
Histotype
MFH 96 0.65 33
Leiomyosarcoma 48 0.62 18
Liposarcoma 39 0.76 12
Synovial sarcoma 17 0.71 6
Other than above 59 0.48 31
Malignancy grade
I 13 1.00 0
II 38 0.84 7
III 82 0.69 29
IV 126 0.47 64
Tumour necrosis
No 129 0.82 24
Yes 127 0.41 76
Vascular invasion
No 188 0.71 56
Yes 67 0.37 43
Microscopic tumour necrosis determined in 256 patients. Vascular invasion
determined in 255 patients. MFSR = metastasis-free survival rate; MFH =
malignant fibrous histocytoma.
Table 2 Flow cytometric SPF values and prognostic strength in 259 soft tissue sarcomas of the loco-motor system, calculated with different methods
Method A B C D E F G H I
Baisch 159 7.8 6.0 0.1–25 e 3.4 3 46/113 0.94/0.53 4/7
ae 11.0
No corr 253 13.6 11.5 0–47.5 e 4.0 9 102/151 0.76/0.53 6/30
ae 16.4
Exp 253 9.5 7.1 0–45.1 e 2.4 3 77/176 0.82/0.53 4/17
ae 10.8
Exp-clust 253 6.0 4.0 0–33.1 e 1.5 8 188/65 0.67/0.50 7/67
ae 6.1
Slice 253 10.5 8.5 0–44.5 e 2.8 9 135/118 0.75/0.47 6/39
ae 12.5
Slice-clust 253 6.5 4.5 0–33.9 e 1.9 5 135/118 0.72/0.51 5/41
ae 6.8
A = total number possible to calculate; B = mean SPF value (%); C = median SPF value (%); D = range (%); E = median SPF value (%); F = optimal cut-off
values (%) found after step-wise analysis of maximum separation between curves in a Kaplan–Meier plot; G = number of patients in groups; H = 5-year
metastasis’ free survival rate with optimal cut-off, ‘good’ group/‘bad’ group; I = in ‘good’ group: number of patients with metastasis after 5 years/total number of
patients with metastasis. No corr = no background correction. Exp = exponential background correction. Exp-clust = exponential background correction with
cluster compensation. Slice = correction for slices. Slice-clust = correction for slices and clusters. e = euploid. ae = aneuploid. SPF = S-phase fraction.background contribution is performed. This method has been
reported to be of prognostic value in several malignancies other
than STS: breast cancer, endometrial cancer and prostate cancer.
However, this model requires considerable experience with non-
automatic DNA analysis interpretation for objective and repro-
ducible results (Baldetorp et al, 1995; St￿l and Baldetorp, 1998). In
the parametric models all compartments of the DNA histogram are
mathematically estimated by e.g. a least square curve-fitting tech-
nique, which may produce objective and reproducible results on all
parameters of the DNA histogram. However, regardless of the
method used, it is impossible to validate the correctness in the
background correction. Thus, the final SPF calculation may well be
data without relevance to tumour kinetics and/or clinical course.
Furthermore, it is difficult to define objective criteria regarding
background distribution and/or the size of the DNA stemline to be
analysed to permit a reliable calculation of SPF. Attempts to recom-
mend different types of mathematical correction models for SPF in
various settings have been made (Beck, 1980; Bagwell et al, 1991;
Rabinovitch, 1991), and at a consensus conference experiences
were pooled into general recommendations and guidelines for clin-
ical DNA flow cytometry (Shankey et al, 1993).
Huuhtanen et al (1996) analysed 155 paraffin-embedded STS,
using MultiCycle with the sliced nuclei option for background
subtraction. SPF could be calculated in all patients, and three
subgroups were used. A high SPF predicted a shorter survival in
patients with diploid tumours. Gustafson et al (1997) analysed 260
paraffin-embedded tumours using the Baisch method. SPF could be
calculated in 160 of these tumours, and two subgroups were used.
High SPF (> 3.0%) was an independent prognostic factor for metas-
tasis. Collin et al (1997) found SPF ‡ 4% calculated according to the
Baisch method to be an independent prognostic factor for tumour
death in 132 patients with STS. Also in this series the reported
failure rate was 40%, despite the use of frozen material.
We have earlier shown that patients in whom calculation of SPF
according to Baisch failed have a different distribution of histo-
types and malignancy grades, and a worse 5-year MFSR, implying
that they may belong to a different subset of STS patients
(Gustafson et al, 1997). In the present series, using the MultiCycle
software, it was possible to calculate the SPF in the majority of
cases where the Baisch method failed. However, the survival for
the ￿poor prognosis￿ group using MultiCycle was not significantly
separated from the ￿poor prognosis￿ group using the Baisch
method. On the other hand, the survival for the ￿good prognosis￿
group was worse using MultiCycle than using Baisch. It is obvious
that the Baisch method, using international consensus guidelines
on when not to calculate SPF, inherently selects a group of patients
with good prognosis. In a large series of breast cancers, SPF calcu-
lation using the Baisch model gave results with higher prognostic
significance that models using background correction (Baldetorp
et al, 1998).
The possibility to identify patients who will metastasize late is
of clinical importance; they may be at risk of developing metas-
tasis and/or local recurrence for a longer time-period, and may
require a longer follow-up period (Gustafson et al, 1997).
We conclude that for clinical use in STS, despite a high failure
rate, SPF should be calculated using the Baisch planimetric
method when using paraffin archival material. This model gives
the best prognostic separation in metastasis-free survival, and also
the possibility to identify patients who require a longer follow-up.
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